A carregar...
Downregulation of miR-222-3p Reverses Doxorubicin-Resistance in LoVo Cells Through Upregulating Forkhead Box Protein P2 (FOXP2) Protein
BACKGROUND: Doxorubicin (DOX) is a potent chemotherapeutic agent used to treat colon cancer. Despite impressive initial clinical responses, drug resistance has dramatically compromised the effectiveness of DOX. However, the underlying mechanisms of chemotherapeutic resistance in colon cancer remain...
Na minha lista:
| Publicado no: | Med Sci Monit |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Scientific Literature, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6442496/ https://ncbi.nlm.nih.gov/pubmed/30904920 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.913325 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|